These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 386790)

  • 41. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 42. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead.
    Hayes TA
    Clin Pharmacol Ther; 1998 Jun; 63(6):607-16. PubMed ID: 9663174
    [No Abstract]   [Full Text] [Related]  

  • 44. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 45. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A proposal for financing postmarketing drug safety studies by augmenting FDA user fees.
    Carpenter D
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-469-80. PubMed ID: 16234281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk management and intrusions on medical practice: striking a balance.
    Enzi MB; Kennedy EM
    Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL; Iyasu S
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Prescription Drug Marketing Act of 1987.
    Greenberg RB
    Am J Hosp Pharm; 1988 Oct; 45(10):2118-26. PubMed ID: 3228083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Importing a change in diet: the proposed food safety law of 2010 and the possible impact on importers and international trade.
    May SG
    Food Drug Law J; 2010; 65(1):1-35, i. PubMed ID: 24475533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Marketing approval for the lithotripter.
    Nightingale SL; Young FE
    Isr J Med Sci; 1986; 22(7-8):519-23. PubMed ID: 3781809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Policy developments in regulatory approval.
    Temple R
    Stat Med; 2002 Oct; 21(19):2939-48. PubMed ID: 12325110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Status of generic substitution: problematic drug classes reviewed.
    Ross MB
    Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDA marketing claims, and the practitioner.
    Runner S
    J Evid Based Dent Pract; 2006 Mar; 6(1):19-23. PubMed ID: 17138391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The drug approval process and the information it provides.
    Myers A; Moore SR
    Drug Intell Clin Pharm; 1987 Oct; 21(10):821-6. PubMed ID: 3322757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007.
    Gruber MF
    Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abandoning hopelessness. Reform of the U.S. Food and Drug Administration (FDA).
    Baker R
    BETA; 1995 Dec; ():6-7. PubMed ID: 11363013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent legal developments and the authority of the Australian Therapeutic Goods Administration.
    Shirlow E; Faunce T
    J Law Med; 2009 May; 16(5):764-9. PubMed ID: 19554858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.